Thomas Gervais, head of MSAT Business Unit at Samsung Biologics talks about some of the key issues currently affecting biologics processing.
Q) Bioprocessing at commercial scale is becoming truly industrial in scope. Given your offerings and capabilities, what protein/gene expression or chemistry platforms are offering developers and sponsors better yields, efficiencies, and programme success?
A) There are many contributors to achieving programme success, however, we believe one of the most impactful factor is the use of a CHO platform for the expression of monoclonal antibodies or Fc-fusion proteins. The CHO platform provides predictable performance across scales to facilitate technical transfer and reduce the overall batch failure rate. Although we cannot eliminate the inherent variability in biologics manufacturing, this platform enables the understanding of those components that are controllable.